Navigation Links
Hana Biosciences Announces Data to be Presented On Talvesta,(Talotrexin) for Injection at The American Association for Cancer,Research Annual Meeting

SOUTH SAN FRANCISCO, Calif., April 11, 2007 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on advancing cancer care, will present preclinical data for Talvesta(tm) (talotrexin) for Injection at the American Association for Cancer Research 100th Annual Meeting April 14-18, 2007 in Los Angeles, California.

Abstract No. 2210: "Combining talotrexin (PT-523) with paclitaxel in A549 non-small cell lung cancer (NSCLC) athymic nude mice xenografts" will be presented in a poster session on Monday, April 16, 2007 from 8:00am to 12:00pm PDT, in Poster Section 23, Tumor Biology 15, in the Exhibit Hall. Board No. 8.

About Talvesta(tm) (talotrexin) for Injection

Talvesta(tm) is a novel nonpolyglutamable antifolate drug under development for the treatment of various types of cancers. Talvesta has demonstrated enhanced antitumor activity in a broad spectrum of preclinical studies by targeting the enzyme DHFR to prevent DNA synthesis in tumor cells and inhibit tumor growth. These studies suggest that Talvesta, as compared to methotrexate, enters into cells up to ten times more efficiently and demonstrates 10- to 100-fold more potency in overcoming polyglutamation, a well-established mechanism of antifolate resistance. Talvesta also binds more tightly to its anti-tumor target DHFR, which Hana believes may further inhibit tumor growth. In May 2006, the U.S. Food and Drug Administration granted orphan drug designation for Talvesta in patients with ALL.

About Hana Biosciences, Inc.

Hana Biosciences, Inc. (Nasdaq:HNAB) is a South San Francisco, CA-based biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to advance cancer care. The company is committed to creating value by building a world-class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner o
'"/>




Page: 1 2 3

Related medicine technology :

1. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
2. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
3. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
4. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:7/25/2014)... Ore. , July 25, 2014  Semler ... an emerging medical risk assessment company that develops ... patients and evaluating chronic diseases, today reported financial ... ended June 30, 2014. "The ... for Semler," said Doug Murphy-Chutorian , M.D., ...
(Date:7/25/2014)... July 25, 2014 /PRNewswire-iReach/ -- Dr. Michael Gabriel ... Pediatrics, reacts to a recent study, which shows how grief ... - http://photos.prnewswire.com/prnh/20140723/129709 According to ... stress are more likely than others to grow up overweight ... There were two specific types of stress that ...
(Date:7/24/2014)... Wis. , July 24, 2014  Restore ... specialty and compounded pharmaceuticals, announced that it is ... information unique to each individual based upon their ... possible by understanding the interaction between a patient,s ... "We,re very excited to provide this new ...
Breaking Medicine Technology:Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3
... 2012    Octapharma USA has submitted its Biological License ... Food and Drug Administration (FDA) with the goal of ... 2012. The FDA will evaluate the octaplasLG® ... patients who require replacement of multiple plasma coagulation factors. The ...
... 27, 2012  Ventana Medical Systems, Inc. (Ventana), a member of ... Food and Drug Administration (FDA) for the VENTANA Companion ... VENTANA iScan Coreo Au scanner running ... offering an FDA cleared Ki-67 image analysis algorithm for ...
Cached Medicine Technology:Octapharma USA Submits BLA for octaplasLG®, a Therapy Targeting Adverse Transfusion Events 2Octapharma USA Submits BLA for octaplasLG®, a Therapy Targeting Adverse Transfusion Events 3Ventana Receives FDA Clearance for Ki-67 (30-9) Image Analysis and Digital Read Applications 2
(Date:7/25/2014)... Reproductive Science Center (RSC) of New ... Luzzo, Lead Physician at RSC Rhode Island, received the ... in fertility care and community outreach issued by Providence ... PBN Awards ceremony held July 24th at Salve Regina ... highly regarded, emerging leaders in their field were recognized ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Merrill ... of technology-enabled services for the financial, legal, healthcare ... virtual data room business, Merrill DataSite, has been ... presented by GrowthBusiness at the M&A Awards 2014 ... the achievements of entrepreneurs, management teams, advisors and ...
(Date:7/25/2014)... 2014 A new study of participants in ... are published today in Cancer , found evidence that ... who had an abnormal finding on a lung cancer screening ... life than did those who were screened and found to ... to the researchers. “We expected that participants with an abnormal ...
(Date:7/25/2014)... AZ (PRWEB) July 25, 2014 Hastings ... offering discount attorney’s fees with regard to personal ... Hastings provide a wide range of legal services for ... the negligence of another individual or corporation. Free initial ... determining the validity of a potential personal injury ...
(Date:7/25/2014)... Treatment for lymphoma may lower men,s fertility, new research ... are cancers of the body,s white blood cells, often ... years. For men, treatment for these cancers can harm ... fertility within two years of treatment, the researchers cautioned ... this significant side effect before treatment begins. "While ...
Breaking Medicine News(10 mins):Health News:Dr. Kerri Luzzo of the Reproductive Science Center of Providence Receives “40 Under Forty Award" for Outstanding Professional Accomplishments and Community Outreach 2Health News:Merrill DataSite Recognized as “Technology Provider of the Year” by GrowthBusiness at the M&A Awards 2014 Event 2Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 2Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 4Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 5Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3Health News:Lymphoma Treatment May Harm, Halt Men's Sperm Production 2
... man, who tested negative for the human form of the ... Diseases, in Bucharest// , after he exhibited flu like symptoms. ... H5N1 had infected the birds in the area. ... Bucharest national laboratory. The Ministry of Health has designated the ...
... rising obesity rates by 2010 will fall flat on its face, ... to a recent study// . Though local level work is going ... about the thrust given to this area. The public Health Minister, ... lots left to be done. Obesity has sent the NHS expenditure ...
... and Research Institutes, Inc (NDRI) in New York ... explored the role// of social supports, spirituality, religiousness, ... of recovery from addiction. The study reveals markedly ... as a decrease in stress when people were ...
... A 91-year-old woman in British Columbia died a lonely death after ... sons, is hopeful that his mom’s death// will bring about some ... ,The hospital separated Fanny Albo from her ailing husband who ... in Trail. Fanny Albo and her husband had been together for ...
... to a new Japanese study appearing in the current ... green tea daily may help reduce risk of dementia,.// ... related with the risk of having cognitive impairment in ... , Dr. Shinichi Kuriyama of Tohoku University Graduate ...
... Germany has reported that regular peelings and scrubbing with a ... the skin is stretched during pregnancy. // ,Peelings and ... magazine said. The same is true of massages. ... use of certain substances can help. ...
Cached Medicine News:Health News:Drug Addiction Recovery Buffered by Spirituality 2
Accommodates either eye. Slotted, malleable aluminum surface. Correct size holes produce ideal pin hole effect. Packaged 50 per box....
Blue plastic shield for reduced glare. Packaged 12 per box....
Non-reflective black anodized aluminum. Selection of five pin hole sizes (0.8 mm to 1.5 mm). Overall length: 4.0 inches....
4 mm x 4 mm downward biting jaws, curved right, length of shaft 115 mm, overall length 9.3 inches....
Medicine Products: